Theraputic Evaluation Of Brain Radiotherapy Combined With Temozolomide Chemotherapy To Brain Metastases Of Non-small Cell Lung Cancer

Objective: Evaluation of clinical efficiency and safety of whole brainradiation therapy combined with temozolomide chemotherapy to non-small celllung cancer with brain metastasis.Materials and methods: Collected65patients suffering from non-smallcell lung cancer with brain metastases treated in the First Hospital of JilinUniversity Oncology Center from March2011to March2013.31patientsreceived radiotherapy alone (treatment group),34patients receivedradiotherapy comebined with temozolomide chemotherapy(control group). thepattern of radiotherapy were same between two groups,(whole brainradiotherapy: DT:40Gy/20f/4w), the23patients were eligible to receive theradical dose (:6MV-X ray, DT:10Gy/5f/1w to20Gy/10f/2w). The treatmentgroup received concomitant temozolomide chemotherapy during brainradiotherapy(75mg/m2/d,1/d). Both groups received3.0MRI to evaluate theRR of the brain metastasis, the change of the syndrome and sign, the quality oflife and side effects after4to6weeks. The follow-up time was3to24months.Results: Clinical efficiency:(1) syndrome and sign: control group was64.5%(20/31), the treatment group was94.1%(32/34). There was statisticalsignificance between two groups (χ~2=8.880, Ρ=0.003, Ρ <0.05).(2) Theimprovement of the quality of life: control group (16/31), treatment group (30/34). There was statistical significance between two groups (χ~2=10.513Ρ=0.001, Ρ <0.05).(3) The RR (CR+PR) of the brain metastases: control groupwas54.8%(17/31), treatment group was91.2%(31/34). There was statisticalsignificance between two groups (χ~2=16.292Ρ=0.001, Ρ <0.05).2. The clinical safety: There was no statistical significance between twogroups for side effects (χ~2=4.216, ρ=0.245, Ρ>0.05).3. The median survival time: The data was calculated by Kaplan-Meiermethod, tested by Log-rank. There was no statistical significance between twogroups (χ~2=1.857, Ρ=0.173, Ρ>0.05). The median survival time of controlgroup and treatment group were7.4months and8months, respectively.Conclusion: The combination of radiotherapy and temozolomidechemotherapy is effective and safe to non-small cell lung cancer with brainmetastases. There is no significant increase in side effects and patients arewell tolerated, but the median survival time show no increased.